Research Analysts Set Expectations for QNRX FY2024 Earnings

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) – Stock analysts at Zacks Small Cap lowered their FY2024 earnings per share (EPS) estimates for shares of Quoin Pharmaceuticals in a research note issued to investors on Tuesday, November 12th. Zacks Small Cap analyst M. Marin now anticipates that the company will earn ($2.05) per share for the year, down from their prior estimate of ($2.02). The consensus estimate for Quoin Pharmaceuticals’ current full-year earnings is ($2.05) per share. Zacks Small Cap also issued estimates for Quoin Pharmaceuticals’ FY2025 earnings at ($2.00) EPS.

Quoin Pharmaceuticals Stock Up 2.2 %

Shares of QNRX opened at $0.62 on Thursday. The company has a market capitalization of $3.13 million, a price-to-earnings ratio of -0.15 and a beta of 1.85. Quoin Pharmaceuticals has a 52-week low of $0.48 and a 52-week high of $6.18. The stock has a 50 day moving average price of $0.64 and a 200 day moving average price of $0.65.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Quoin Pharmaceuticals stock. Virtu Financial LLC bought a new position in shares of Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 30,749 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned 0.77% of Quoin Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 8.63% of the company’s stock.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.